STAGE III RECTAL CANCER AJCC V8

This phase II trial tests whether adding the immunotherapy drug nivolumab to the standard two-drug regimen (encorafenib and cetuximab) works better at shrinking tumors in people with a specific type of advanced colorectal cancer (BRAF-mutant, microsatellite stable). About 86 part…

This phase 2 trial is testing whether adjusting treatment based on risk level can improve outcomes for people with HIV who have anal cancer. Low-risk patients receive standard chemotherapy and radiation, while high-risk patients also get the immunotherapy drug nivolumab after sta…

This study tests whether giving two immunotherapy drugs (nivolumab and ipilimumab) along with a short course of radiation can completely eliminate advanced rectal cancer before surgery. About 31 adults with a specific genetic type (MSI-H/dMMR) of stage II or III rectal cancer wil…

This study tests a combination of three drugs (cetuximab, LY3214996, and abemaciclib) in people with advanced colorectal cancer that has spread and no longer responds to standard therapy. The goal is to see if the combination can shrink tumors and improve survival. About 46 adult…

This early-stage study tests the safety of combining the chemotherapy drug TAS-102 with radiation therapy for people with stage II or III rectal cancer that hasn't been treated yet. The goal is to find the safest dose of TAS-102 to use with radiation before surgery to remove the …

This study tests a new drug, SX-682, alone and with the immunotherapy nivolumab, in people with a specific type of advanced colorectal cancer that has spread or cannot be removed. The cancer must have a RAS mutation and be microsatellite stable (MSS), which often makes it harder …

This phase II trial compares a three-drug chemotherapy combination (FOLFIRINOX) against standard two-drug combos (FOLFOX or CAPOX) in 783 patients with locally advanced rectal cancer. The goal is to see if the stronger regimen leads to a complete disappearance of the tumor, poten…

This early-phase trial tests a special PET scan that uses a radioactive tracer (64Cu-M5A) to highlight rectal cancer cells. The goal is to see if this scan can show tumor extent and response more accurately than standard imaging before and after chemotherapy and radiation. About …

This phase II trial tests whether time-restricted eating (intermittent fasting) can reduce side effects from radiation or chemoradiation in people with prostate, cervical, or rectal cancers. About 49 participants will either follow a time-restricted eating plan or receive standar…

This study follows 565 people with stage I-III colon or rectal cancer to understand how treatment affects their finances and quality of life. Participants complete surveys about costs and financial well-being over 12 months. The goal is to help doctors better support patients fac…

This study looks at tiny pieces of cancer cells or DNA floating in the blood of people with rectal cancer. Researchers want to see if these markers can help predict how the tumor responds to standard treatment. About 341 participants, including healthy volunteers, will provide bl…